Neuromuscular blockers and reversal drugs

Cynthia A. Lien, Matthias Eikermann

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Nondepolarizing neuromuscular blocking agents were introduced into clinical practice more than 60 years ago. Throughout the world, millions of patients receive neuromuscular blocking agents as part of their general anesthetic each year. With use, increased recognition of complications, pharmacologic advances, the ability to monitor depth of neuromuscular blockade, and changes in surgical practice, a better understanding of neuromuscular blockade and its reversal is developing. Because of this, long-acting neuromuscular blocking agents are rarely, if ever, used in the clinical setting; new neuromuscular blocking agents that can be easily reversed and new reversal agents that can reverse even profound neuromuscular blockade are being developed. The goal of this work is to ensure that neuromuscular blockade can be easily, quickly, and reliably reversed and that the safety of providing neuromuscular blockade intraoperatively will increase.

Original languageEnglish (US)
Title of host publicationPharmacology and Physiology for Anesthesia
Subtitle of host publicationFoundations and Clinical Application
Number of pages27
ISBN (Electronic)9780323481106
ISBN (Print)9780323776981
StatePublished - Jan 1 2018
Externally publishedYes


  • Neostigmine
  • Neuromuscular blockade
  • Nondepolarizing neuromuscular blocking agents
  • Residual neuromuscular blockade
  • Reversal agents
  • Sugammadex

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Neuromuscular blockers and reversal drugs'. Together they form a unique fingerprint.

Cite this